Special Issue

Personalized Cardiovascular Medicine

Message from the Guest Editor

Personalized medicine is the practice of tailoring medical treatment to the individual characteristics of each patient. Personalized medicine includes identifying patients most likely to benefit and those most likely to experience adverse reactions in response to a drug, and also tailoring therapy based on pharmacokinetics or pharmacodynamic response. This Special Issue of the Journal of Personalized Medicine will highlight the current state of the art and showcase some of the latest findings in the field of personalized cardiovascular medicine. This involves the evaluation of biomarkers, expanded advanced risk factor analysis, micronutrient testing, risk scoring systems, cardiovascular genetics, gene expression testing, and non-invasive and invasive cardiovascular testing, as well as research and debate about the effectiveness of personalized medicine as a more suitable tool for the prevention and treatment of cardiovascular diseases than the traditional one-size-fits-all recommendations. Dr. Agata Bielecka-Dabrowa

Guest Editor

Prof. Dr. Agata Bielecka-Dabrowa

- Department of Cardiology and Congenital Heart Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), 93-338 Lodz, Poland
- 2. Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland

Deadline for manuscript submissions

closed (15 January 2022)



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/75989

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

